Quarterly Activities Report
Filed with ASX · · 5 pages · English
Summary by 6ix AI
Syntara ended the quarter with a strong cash position, reflecting ongoing investments in research and development activities. The company also announced the appointment of a new Company Secretary and provided updates on its ongoing clinical trials and financial performance.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Earlier from Syntara
- Acceleration of skin scarring program
- Placement
- Equity Raising Presentation
- Interim data in Phase 2 study of SNT-5505 in myelofibrosis
- Presentation: Phase 2 study of SNT-5505 in myelofibrosis
Later from Syntara
- SNT-5505 awarded US FDA Fast Track designation
- New positive interim data in Phase 2 study of SNT-5505
- Quarterly Shareholder Report
- Quarterly Appendix 4C Cash Flow Report
- Suspension from Quotation
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara